迈克生物
(300463)
| 流通市值：60.43亿 | | | 总市值：74.19亿 |
| 流通股本：4.96亿 | | | 总股本：6.09亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,075,034,096.39 | 510,257,588.9 | 2,548,756,678.6 | 1,947,615,476.64 |
| 营业收入 | 1,075,034,096.39 | 510,257,588.9 | 2,548,756,678.6 | 1,947,615,476.64 |
| 二、营业总成本 | 1,006,684,937.26 | 466,928,768.32 | 2,321,458,650.01 | 1,641,999,626.83 |
| 营业成本 | 462,706,408.47 | 220,630,373.57 | 1,144,092,241.52 | 833,709,893.93 |
| 税金及附加 | 17,428,601.05 | 5,622,275.41 | 25,870,483.73 | 15,902,077.28 |
| 销售费用 | 274,643,999.86 | 131,445,644.15 | 646,774,559.98 | 437,353,017.09 |
| 管理费用 | 92,083,183.05 | 43,771,432.52 | 165,133,788.84 | 117,401,811.32 |
| 研发费用 | 152,648,404.07 | 61,571,017.19 | 323,153,253.29 | 223,099,816.06 |
| 财务费用 | 7,174,340.76 | 3,888,025.48 | 16,434,322.65 | 14,533,011.15 |
| 其中:利息费用 | 10,405,671.34 | 4,472,959.61 | 22,119,703.17 | 15,138,099.03 |
| 其中:利息收入 | 2,808,099.66 | 902,528.22 | 6,446,920.15 | 4,214,158.3 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -11,594,558.03 | -11,535,012.59 | 2,147,833.79 | -8,668,000.15 |
| 加:投资收益 | 673,958.18 | 673,958.18 | 2,878,947.74 | 3,393,048.87 |
| 资产处置收益 | 1,995,701.15 | -3,422,590.39 | -6,728,015.31 | -5,797,227.7 |
| 资产减值损失(新) | -6,711,053.04 | -1,651,216.3 | -100,824,040.32 | -7,025,194.79 |
| 信用减值损失(新) | -7,889,009.93 | 1,884,965.63 | 9,759,956.39 | 9,064,673.29 |
| 其他收益 | 10,813,882.76 | 5,244,424.92 | 35,432,743.05 | 21,960,273.37 |
| 四、营业利润 | 55,638,080.22 | 34,523,350.03 | 169,965,453.93 | 318,543,422.7 |
| 加:营业外收入 | 546,116.43 | 48,221.41 | 897,255.46 | 1,411,946.35 |
| 减:营业外支出 | 27,775,107.04 | 5,131,687.09 | 46,211,304.08 | 8,671,607.77 |
| 五、利润总额 | 28,409,089.61 | 29,439,884.35 | 124,651,405.31 | 311,283,761.28 |
| 减:所得税费用 | -8,130,815.96 | 3,986,091.13 | 5,887,071.82 | 28,186,766.24 |
| 六、净利润 | 36,539,905.57 | 25,453,793.22 | 118,764,333.49 | 283,096,995.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 36,539,905.57 | 25,453,793.22 | 118,764,333.49 | 283,096,995.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 34,042,488.83 | 23,979,615.55 | 126,805,274.84 | 281,372,336.41 |
| 少数股东损益 | 2,497,416.74 | 1,474,177.67 | -8,040,941.35 | 1,724,658.63 |
| 扣除非经常损益后的净利润 | 63,056,198.41 | 39,825,355.49 | 138,264,333.61 | 291,632,043.62 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.04 | 0.21 | 0.46 |
| (二)稀释每股收益 | 0.06 | 0.04 | 0.21 | 0.46 |
| 八、其他综合收益 | -15,121,818.95 | -14,790,104.16 | -712,340.23 | -9,042,783.88 |
| 归属于母公司股东的其他综合收益 | -15,121,818.95 | -14,790,104.16 | -712,340.23 | -9,042,783.88 |
| 九、综合收益总额 | 21,418,086.62 | 10,663,689.06 | 118,051,993.26 | 274,054,211.16 |
| 归属于母公司股东的综合收益总额 | 18,920,669.88 | 9,189,511.39 | 126,092,934.61 | 272,329,552.53 |
| 归属于少数股东的综合收益总额 | 2,497,416.74 | 1,474,177.67 | -8,040,941.35 | 1,724,658.63 |
| 公告日期 | 2025-08-01 | 2025-04-29 | 2025-04-29 | 2024-10-23 |
| 审计意见(境内) | | | 标准无保留意见 | |